TONIX PHARMACEUTICALS HOLDING CORP.: 10-Q filed 2011-10-07

Name: TONIX PHARMACEUTICALS HOLDING CORP.: 10-Q filed 2011-10-07
Creator: TONIX PHARMACEUTICALS HOLDING CORP.

What TONIX PHARMACEUTICALS HOLDING CORP. reported in its quarterly report filed 2011-10-07 (fiscal Q3 2011): 10 published measures, 30 facts as tagged in accession 0001165527-11-000924.

This filing

Form: 10-Q (quarterly report)
Filed: 2011-10-07
Fiscal period: fiscal Q3 2011
Accession: 0001165527-11-000924 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TONIX PHARMACEUTICALS HOLDING CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2011-09-30	205	USD
At 2010-12-31	4,624	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2011-09-30	15,240	USD
At 2010-12-31	10,306	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2011-09-30	-15,035	USD
At 2010-12-31	-5,681	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2011-07-01 to 2011-09-30	-2,322	USD	92
2011-01-01 to 2011-09-30	-9,353	USD	273
2007-11-16 to 2011-09-30	-80,035	USD	1415
2010-07-01 to 2010-09-30	-3,685	USD	92
2010-01-01 to 2010-09-30	-11,909	USD	273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2011-01-01 to 2011-09-30	-4,419	USD	273
2007-11-16 to 2011-09-30	-74,795	USD	1415
2010-01-01 to 2010-09-30	-10,527	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2011-01-01 to 2011-09-30	0	USD	273
2007-11-16 to 2011-09-30	75,000	USD	1415
2010-01-01 to 2010-09-30	2,000	USD	273

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2011-09-30	59,500	USD
At 2010-12-31	59,500	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2011-07-01 to 2011-09-30	1,122	USD	92
2011-01-01 to 2011-09-30	3,453	USD	273
2007-11-16 to 2011-09-30	26,954	USD	1415
2010-07-01 to 2010-09-30	2,385	USD	92
2010-01-01 to 2010-09-30	4,909	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2011-01-01 to 2011-09-30	0	USD	273
2007-11-16 to 2011-09-30	65,000	USD	1415
2010-01-01 to 2010-09-30	0	USD	273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2011-01-01 to 2011-09-30	4,934	USD	273
2007-11-16 to 2011-09-30	5,240	USD	1415
2010-01-01 to 2010-09-30	957	USD	273

Inspect the source

Entity: TONIX PHARMACEUTICALS HOLDING CORP. / CIK 0001430306
Captured: 2026-09-20 09:02 UTC
SEC response SHA-256: c58b9668b329c3fe1faf138366f8781d658cf50824bc6e133ce4aa43029ca9ed

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001430306.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))